- Drugs
- Tuesday, 26 May 2020
Newleaf Brands Announces Newest Newleaf Brands Advisor Appointee, Dr. Aubrey Oliver, set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts
In recent years, Dr. Oliver was the Coordinating Physician with Caribbean Clinical Research Associates on the first clinical research of its kind which dealt with CBD oil, nano liposome, and alcohol-based forms to find out the absorbency efficacy on healthy cells. Additionally, Dr. Oliver is a certified bioenergetics therapist for cell regeneration and rejuvenation while activating the patient's own stem cells. He is a healing arts specialist with an interest in cannabis and phytonutrients and focuses on a holistic approach towards adrenal exhaustion and aging issues, oncology, infectious diseases and biotoxin illnesses, as well as blood sugar and blood pressure issues.
Damon Michaels, Co-founder of Mydecine and COO of NewLeaf ,remarked, "We believe working with Dr. Oliver is going to help us expand the cutting edge of Mydecine in many ways. With Dr. Oliver's extensive knowledge for treating people with homeopathic medicine, developing research groups, and understanding unique route administration, we will be able to take the fungi formulations in development to a whole new level."
Dr. Oliver is a strong, well-known member of the Jamaican community and will be working with Mydecine to find ways for the Company to expand its efforts into the Caribbean nation.
Dr. Oliver remarked, "I'm grateful and humbled to be announced as an advisor with Newleaf Brands. Over the years, I have been looking for the right vehicle to be able to make a powerful healing impact on my beloved island nation of Jamaica. When I understood the path that Newleaf Brands was going down to advance medicine in order to help many, it was a no brainer for me to join this innovative group. I am happy to now be a key asset to contribute to developing things like a treatment facility and setting up a program for patients and clinicians in our beautiful paradise."
Related Industry Updates
Novartis AG to acquire The Medicines Company
Nov 25, 2019
Acute Pancreatitis Market is expected to reach US$ 8,827.37 million by 2030
Sep 08, 2023
Sarcopenia Treatment Market is expected to reach US$ 5,264.76 million by 2030
Dec 01, 2023
Applied BioMath, LLC Announces Collaboration with Northern Biologics
Apr 22, 2020
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
Jun 27, 2020
The ITC Complaint Against Estar Medical in the U.S. Is Withdrawn by Regenlab
Mar 05, 2020
US Physiological Saline Market is expected to reach US$ 3,910.28 million by 2030
Dec 21, 2023